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Use, misuse, and diversion of attention deficit hyperactivity disorder (ADHD) stimulant drugs 
has significantly increased especially in adolescent populations.  Adolescence is a key stage of 
development in which the brain undergoes sexually dimorphic changes brought about by 
synaptic pruning, and further structural modification. The psychostimulant methylphenidate 
(MPD), commonly prescribed as Ritalin® for ADHD, causes an overall increase of dopamine 
concentration within the mesocorticolimbic pathway, and may result in neuroplastic alterations 
in adolescence leading to nuerobiobehavioral alterations in adulthood. Previous studies in our 
lab demonstrated that there are female-specific effects in behavioral cross-sensitization caused 
by a methylphenidate exposure during early adolescence (P22-31). Behavioral cross-
sensitization is a hallmark of addiction and manifests as locomotor activity, which stems from 
neuroplastic changes.  We hypothesize that methylphenidate exposure during late adolescence 
(P42-51) will result in unique sex-specific behavioral cross-sensitization effects in adulthood 
compared to early adolescence and saline controls. Male (n=41) and female (n=51) C57Bl/6J 
mice were injected (i.p.) with 1.0mg/kg MPD during late adolescence followed by a subacute 
challenge dose of 0.5mg/kg methamphetamine or saline during adulthood (P90). At P90, 
behavioral cross-sensitization was assessed using an open field chamber.  Behavioral 
sensitization was operationalized by analysis of XY ambulation and fine motor movements. 
Preliminary analysis indicates cross-sensitization in MPD-exposed males and females but not 
between them, as was demonstrated after early adolescent exposure.  Therefore, these data 
suggest the developmental boundary for male MPD-induced cross-sensitization exists in a 
critical developmental window between early and late adolescence. These collective results 
support the importance of considering both sex and developmental stage in clinical prescription 
practices, especially since we report an adolescent MPD-induced increase and subsequent adult 
addiction susceptibility.     
 
